Scienture Holdings, Inc. Total Liabilities
Scienture Holdings, Inc. total liabilities. Based on the latest financial reports, Scienture Holdings, Inc. (SCNX) has total liabilities worth $23.63 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Scienture Holdings, Inc.'s assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Scienture Holdings, Inc. (2006–2025)
Total liabilities of Scienture Holdings, Inc. from 2006 to 2025. This chart illustrates how Scienture Holdings, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore SCNX long-term investments to assets to see how much of total assets are deployed in long-term investments.
Scienture Holdings, Inc. Competitors by Total Liabilities
The table below lists competitors of Scienture Holdings, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Floyd Public Company Limited
BK:FLOYD
|
Thailand | ฿123.12 Million |
|
Generic Engineering Construction and Projects Limited
NSE:GENCON
|
India | Rs1.89 Billion |
|
Devonian Health Group Inc
V:GSD
|
Canada | CA$1.65 Million |
|
Texmo Pipes and Products Limited
NSE:TEXMOPIPES
|
India | Rs1.37 Billion |
|
CNPLUS Co. Ltd.
KQ:115530
|
Korea | ₩46.16 Billion |
|
Ennogie Solar Group A/S
CO:ESG
|
Denmark | Dkr57.10 Million |
|
Inovalis Real Estate Investment Trust
TO:INO-UN
|
Canada | CA$188.30 Million |
|
Sab Events & Governance Now Media Limited
NSE:SABEVENTS
|
India | Rs32.97 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Scienture Holdings, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Scienture Holdings, Inc. balance sheet assets.
Liquidity & Leverage Metrics
Scienture Holdings, Inc. Total Liabilities Ratios Explained
Scienture Holdings, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scienture Holdings, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scienture Holdings, Inc. (2006–2025)
The table below shows the annual total liabilities of Scienture Holdings, Inc. from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $14.06 Million | -45.47% |
| 2024-12-31 | $25.78 Million | +115.02% |
| 2023-12-31 | $11.99 Million | +256.10% |
| 2022-12-31 | $3.37 Million | +68.70% |
| 2021-12-31 | $2.00 Million | +79.25% |
| 2020-12-31 | $1.11 Million | -22.20% |
| 2019-12-31 | $1.43 Million | +3.50% |
| 2018-12-31 | $1.38 Million | +48.80% |
| 2017-12-31 | $929.41K | -37.42% |
| 2016-12-31 | $1.49 Million | -15.65% |
| 2015-12-31 | $1.76 Million | +217.99% |
| 2014-12-31 | $553.68K | +102.81% |
| 2013-12-31 | $273.00K | +169.78% |
| 2012-12-31 | $101.19K | +778.03% |
| 2011-12-31 | $11.53K | -99.98% |
| 2008-12-31 | $48.70 Million | +239975.92% |
| 2007-12-31 | $20.28K | +479.54% |
| 2006-12-31 | $3.50K | -- |
About Scienture Holdings, Inc.
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of… Read more